The SEER Inquiry System (SINQ) is a searchable collection of questions that cancer registrars have had while coding cancer cases. These are questions submitted by designated registrars in SEER registries. The questions are answered by expert staff and go through a rigorous review process by NCI SEER staff and designated SEER registry staff before being added to SINQ.

Click Search to look for specific questions in SINQ or to select questions for a Report.

If you cannot find an answer to your question, refer to the Ask a SEER Registrar page.

Recent Questions
<< First    < Prev 10    11 to 20 of 2279    Next 10 >    Last >>
Add to Report ID Question Status Last Updated

Reportability--Brain and CNS:  Are lipomas of the spinal column reportable as a benign tumor of the central nervous system (CNS)? This is seen occassionally at our pediatric facility.

Final Apr 09 2021

Primary site--Breast:  Patient was diagnosed with invasive ductal carcinoma of the left breast. Site of mass is 2:00 to 3:00. What is the correct site code, C504 upper outer quadrant (UOQ) or C50.8 (overlapping)?

Final Apr 09 2021

Multiple primaries--Heme and Lymphoid Neoplasms:  Is a patient with peripheral blood initially showing chronic myelogenous leukemia (CML), lymph node biopsy showing granulocytic sarcoma (9930/3), and bone marrow biopsy showing acute myeloid leukemia (AML) one or two primaries?  See Discussion.

Final Apr 09 2021

Histology/Biliary tract--Ampulla of Vater:  What is the histology code for Intra ampullary papillary-tubular neoplasm in association with microinvasion? See discussion.

Final Apr 09 2021

Reportability--Heme and Lympoid Neoplasms--Polycythemia vera:  Is secondary polycythemia vera reportable?  See Discussion.


Final Mar 30 2021

Multiple primaries--Heme & Lymphoid Neoplasms--Lymphoma:  Is a case initially submitted as C772 with histology coded 9591/3 (lymphoma, NOS) with a second case submitted as C162 with histology coded 9699/3 (extranodal marginal zone lymphoma of mucosal-associated lymphoid tissue (MALT lymphoma) a single primary or multiple primaries? See Discussion.

Final Mar 30 2021

Primary site--Ovary:  What information takes precedence for coding the primary site in cases with high grade serous carcinoma that are clinically called ovarian but on pathology, the pathologist calls the primary site fallopian tube and the gynecology oncology/managing phsyician continues to call the cases ovarian.  Both the ovary and tube are involved. Sometimes also referred to as "tubo-ovarian."

Final Mar 30 2021

Primary Site--Vulva:  What is the primary site of patient with an excision of a left vulvar cystic mass showing focal mammary-type ductal carcinoma in situ (DCIS) on 11/06/2020?  See Discussion.

Final Mar 30 2021

Reportability/Terminology--Head & Neck:  Is an "evolving" squamous cell carcinoma of the vermillion border of the left lower lip reportable?

Final Mar 30 2021

Solid Tumor Rules (2018/2021)/Multiple primaries--Prostate:  Is basal cell carcinoma with focal squamous differentiation and a small focus of infiltrating prostatic adenocarcinoma one or two primaries and if one, is the histology 8147/3? See Discussion.

Final Mar 26 2021
< Prev 10    Next 10 >